Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Thumbnail

Theranostic nanomedicine: Q&A with Weibo Cai, PhD

As the use of theranostic nanoparticles in nuclear medicine and molecular imaging expands, it becomes clearer which technologies will have enough traction to be translated to clinical practice. Molecular Imaging caught up with Weibo Cai, PhD, associate professor and head of the University of Wisconsin Molecular Imaging and Nanotechnology Lab in Madison, to find out more about the leading research in theranostic nanomedicine.

Philips partners with Image Stream Medical to expand its integration solutions for image-guided minimally invasive therapies

Royal Philips, a leader in image-guided therapies, announced that it has signed an agreement with Image Stream Medical (ISM) that allows Philips to further expand its integration solutions for its hybrid suite and interventional lab solutions with integrated video and live streaming capabilities. As part of the agreement, Philips has acquired a minority stake in ISM. Financial terms of the agreement were not disclosed.

Thumbnail

Quantifying cardiac PET: MFR may be more consistent than MBF

There are a few different quantitative techniques used to measure myocardial blood flow (MBF) and myocardial flow reserve (MFR), both of which have been shown to provide useful information in managing cardiovascular disease. However, MFR measurements appear to be less affected by variables of quantitation when using different arterial input functions and extraction models, according to a comparison study published today in the Journal of Nuclear Medicine.

Definiens predicts biggest drivers for personalized medicine in 2015: Data quality, immunotherapy, combination treatments and predictive biomarkers

Major opportunities are on the horizon for personalized medicine and clinical cancer research and treatment, according to Definiens, the global leader in Tissue Phenomics for oncology diagnostics. The company predicts that the biggest trends driving the industry over the next year will include big data and data quality, immunotherapy, combination treatments and predictive biomarkers. However, as the industry seeks to overcome unique challenges in each of these areas, advancements will rely on adoption of key drivers.

Novel PET agent reveals inflammation in Alzheimer’s brain

A new method of Alzheimer’s imaging has arrived with an investigative agent that reveals neuro-inflammation via microglia expression of the protein TSPO, according to a scientific presentation Nov. 17 during Neuroscience 2014, the meeting of the Society of Neuroscience, in Chicago.

Thumbnail

Hunger hormone could signal treatments for Parkinson’s

As Americans anticipate their Thanksgiving dinners, the gnawing sensation of hunger prepares them to eat perhaps too much turkey or pumpkin pie. The same hormone that produces that sensation of hunger could be the secret to a new therapy protecting Parkinson’s patients from disease-related cell death, according to research presented Nov. 16 during the Society of Neuroscience’s annual meeting in Chicago.

Thumbnail

Breast cancer model could usher in new generation of imaging, therapy

A trifecta of cells has been revealed to be the crux of breast cancer metastases. The discovery provides cutting-edge details that could revolutionize the development of diagnostic testing and therapeutic agents for breast cancer, officials at the Albert Einstein College of Medicine in New York announced yesterday.

Thumbnail

Autopsy shows Williams had DLB

The recent death of the beloved comedian and actor Robin Williams by suicide took fans by complete surprise and left many in mourning for the master of improvisation. A recent report in Salon provides details from Williams' autopsy report that indicates the presence of dementia with Lewy bodies (DLB), which may explain some of his uncharacteristic behavior of late. In addition to DLB, Williams also suffered from Parkinson's.

Around the web

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.